PROPOSED RULE MAKING



CR-102 (June 2024) (Implements RCW 34.05.320)

Do **NOT** use for expedited rule making

CODE REVISER USE ONLY

OFFICE OF THE CODE REVISER STATE OF WASHINGTON FILED

DATE: October 01, 2024

TIME: 11:33 AM


WSR 24-20-117

Agency: Health Care Authority								
☑ Original Notice								
□ Supplemental Notice to WSR								
□ Continuance of WSR								
□ Preproposal Statement of Inquiry was filed as WSR 24-14-076; or								
□ Expedited Rule MakingProposed notice was filed as WSR; or								
☐ Proposal is exempt under RCW 34.05.310(4) or 34.05.330(1); or								
□ Proposal is exempt under RCW								
Title of rule and other identifying information: (describe subject)								
WAC 182-52-0050 Prescription drug affordability board – Data and confidentiality WAC 182-52-0095 Prescription drug affordability board – Upper payment limits – Public comment								
Hearing location(s):	scription are	ig anordability board – oppe	payii	ient iimits – r ubiic comment				
Date:	Time:	Location: (be specific)		Comment:				
November 5, 2024	10:00 AM	The Health Care Authority	holds	To attend the virtual public hearing,				
		public hearings virtually wit	hout a	you must register in advance:				
		physical meeting place		https://us02web.zoom.us/webinar/register/WN_yD-				
				r9EuYSnSoSXrF38FcTQ				
				If the link above opens with an error message, please				
				try using a different browser. After registering, you will receive a confirmation email containing information				
				about joining the public hearing				
Date of intended ado	ption: Nove	mber 6, 2024 (Note: Th	nis is N	OT the effective date)				
Submit written comm	ents to:		Assis	ance for persons with disabilities:				
Name HCA Rules Coordinator			Contact Johanna Larson					
Address PO Box 4271	6, Olympia \	WA 98504-2716	Phone 360-725-1349					
Email arc@hca.wa.go	V		Fax 360-586-9727					
Fax 360-586-9727			TTY Telecommunication Relay Service (TRS): 711					
Other			Email Johanna.Larson@hca.wa.gov					
Beginning (date and	time) Octo	ober 2, 2024, 8:00 AM	Other					
By (date and time) November 5, 2024, by 11:59 PM			By (date) October 18, 2024					
Purpose of the proposal and its anticipated effects, including any changes in existing rules: The agency is amending								
this rule to add language about data sharing between the prescription drug affordability board and the health care cost transparency board to align with language in RCW 70.390.050 (revised under Engrossed Substitute House Bill 1508, Chapter								
80, Laws of 2024, Sec 2, (2)(a)). Additionally, the agency is adding a new section regarding a time frame of 30 days for public								
comment prior to the board setting an upper payment limit to align with RCW 42.30.250 (new section created by Substitute								
House Bill 1105, Chapter 171, Laws of 2024, Sec 1, (1))								
Reasons supporting proposal: See Purpose								
Statutory authority for adoption: RCW 41.05.021, 41.05.160								
	•	<u> </u>		or 80 Laws of 2024 Sec 2 (2)(a)) RCW 42 30 250				
Statute being implemented: RCW <u>70.390.050</u> (ESHB 1508, Chapter 80, Laws of 2024, Sec 2, (2)(a)), RCW 42.30.250 (SHB 1105, Chapter 171, Laws of 2024, Sec. 1, (1)),								

Is rule necessary because of a:							
Federal Law? □ Yes ☑ N							
Federal Co	□ Yes ⊠ No						
State Cour	State Court Decision?						
If yes, CITATION	:						
Agency comments or recommendations, if any, as to statutory language, implementation, enforcement, and fiscal matters: None							
Name of proponent: (person or organization) Health Care Authority Type of proponent: □ Private. □ Public. ☒ Governmental.							
Name of agency	personnel responsible for:						
	Name	Office Location	Phone				
Drafting	Valerie Freudenstein	PO Box 42716 Olympia, WA 98504-2716	360-725-1344				
Implementation	Mike Neuenschwander	PO Box 42716, Olympia, WA 98504	360-725-0944				
Enforcement	Mike Neuenschwander	PO Box 42716, Olympia, WA 98504	360-725-0944				
	-	quired under <u>RCW 28A.305.135</u> ?	☐ Yes ⊠ No				
If yes, insert state	ement here:						
The public may obtain a copy of the school district fiscal impact statement by contacting: Name Address Phone Fax TTY Email Other Is a cost-benefit analysis required under RCW 34.05.328? Yes: A preliminary cost-benefit analysis may be obtained by contacting: Name Address Phone Fax TTY Email Other No: Please explain: RCW 34.05.328 does not apply to Health Care Authority rules unless requested by the Joint Administrative Rules Review Committee or applied voluntarily.							
Regulatory Fairness Act and Small Business Economic Impact Statement Note: The Governor's Office for Regulatory Innovation and Assistance (ORIA) provides support in completing this part.							
(1) Identification of exemptions: This rule proposal, or portions of the proposal, may be exempt from requirements of the Regulatory Fairness Act (see chapter 19.85 RCW). For additional information on exemptions, consult the exemption guide published by ORIA. Please check the box for any applicable exemption(s): □ This rule proposal, or portions of the proposal, is exempt under RCW 19.85.061 because this rule making is being adopted solely to conform and/or comply with federal statute or regulations. Please cite the specific federal statute or regulation this rule is being adopted to conform or comply with, and describe the consequences to the state if the rule is not adopted. Citation and description:							
 □ This rule proposal, or portions of the proposal, is exempt because the agency has completed the pilot rule process defined by RCW 34.05.313 before filing the notice of this proposed rule. □ This rule proposal, or portions of the proposal, is exempt under the provisions of RCW 15.65.570(2) because it was adopted by a referendum. 							

	This rule	proposal, or portions of the proposal, is exe	empt under R	CW 19.85.025(3). Check all that apply:				
		RCW 34.05.310 (4)(b)	\boxtimes	RCW 34.05.310 (4)(e)				
		(Internal government operations)		(Dictated by statute)				
		RCW 34.05.310 (4)(c)		RCW 34.05.310 (4)(f)				
		(Incorporation by reference)		(Set or adjust fees)				
		RCW 34.05.310 (4)(d)		RCW 34.05.310 (4)(g)				
		(Correct or clarify language)		((i) Relating to agency hearings; or (ii) process				
				requirements for applying to an agency for a license or permit)				
	This rule	proposal, or portions of the proposal, is exe	empt under R	CW 19.85.025(4). (Does not affect small businesses).				
		proposal, or portions of the proposal, is exe						
Exp	olanation	of how the above exemption(s) applies to the	ne proposed r	ule:				
(2)	Scope o	of exemptions: Check one.						
			Exemptions ic	lentified above apply to all portions of the rule proposal.				
				exemptions identified above apply to portions of the rule				
		ut less than the entire rule proposal. Provide						
		proposal: Is not exempt. (Complete section						
		usiness economic impact statement: Con	•	• •				
	ny portio business		it impose moi	re-than-minor costs (as defined by RCW 19.85.020(2))				
	☐ No Briefly summarize the agency's minor cost analysis and how the agency determined the proposed rule did not impose more-than-minor costs.							
	☐ Yes Calculations show the rule proposal likely imposes more-than-minor cost to businesses and a small business economic impact statement is required. Insert the required small business economic impact statement here:							
	The p		ss economic	impact statement or the detailed cost calculations by				
	Na	ame						
		ddress						
		none						
Fax TTY								
		nail						
		ther						
Da		per 1, 2024	Signatu	ure:				
Name: Wendy Barcus				Mondy Baray				
Title: HCA Rules Coordinator				, 200 may 13 m				

- WAC 182-52-0050 Prescription drug affordability board—Data and confidentiality. (1) For the purpose of reviewing drug prices and conducting affordability reviews, the board (as established in chapter 70.405 RCW) and the health care cost transparency board (established in chapter 70.390 RCW) may share data with each other and access all data collected under RCW 43.71C.020 through 43.71C.080 and any analysis prepared by the authority.
- (2) Advisory group members may not access or review any confidential information.
- (3) The information collected by the board pursuant to RCW 70.405.040 is not subject to public disclosure under chapter 42.56 RCW.
- (4) The authority provides data only after the data recipient, as defined by this chapter, has signed a nondisclosure agreement. The authority may prohibit access to or use of the data by a data recipient who violates the nondisclosure agreement.
 - (5) Data recipients must keep data confidential by:
- (a) Accessing, using, and disclosing information only in accordance with this section and consistent with applicable statutes, regulations, and policies;
- (b) Having a public policy purpose to access and use the confidential information according to chapter 70.405 RCW;
- (c) Protecting all confidential information against unauthorized use, access, disclosure, or loss by employing reasonable security measures in alignment with the agency information system security plan, including physically securing any computers, documents, or other media containing confidential information and viewing confidential information only on secure workstations in nonpublic areas;
- (d) Destroying all confidential information according to document retention requirements;
- (e) Adhering to the confidentiality requirements in this section after the data recipient is no longer an authorized data recipient under chapter 70.405 RCW; and
- (f) Acknowledging that the data recipient may be responsible for liability arising from misuse of the data.
 - (6) Data recipients must not:
- (a) Disclose any confidential information, as defined by WAC 182-52-0010, or otherwise publicly release the confidential information;
- (b) Use or disclose any confidential information for any commercial or personal purpose, or any other purpose that is not authorized in chapter 70.405 RCW;
- (c) Attempt to identify people who are the subject of the confidential information;
- (d) Discuss confidential information in public spaces in a manner in which unauthorized individuals could overhear;
- (e) Discuss confidential information with unauthorized individuals, including spouses, domestic partners, family members, or friends;
- (f) Have any conflicts of interests under the Ethics in Public Service Act that would prevent the data recipient from accessing or using confidential information; and



NEW SECTION

WAC 182-52-0095 Prescription drug affordability board—Upper payment limits—Public comment. The board must allow 30 calendar days for the submission of public comment before setting an upper payment limit. Prior to the 30-day comment period, the authority will notify the public of both the beginning and ending dates that written comment will be accepted.

[1] OTS-5830.1